Recurrence prevention of kidney stones - pharmacologic and dietary measures Abstract. Kidney stone episodes are traumatic events for affected patients and the risk of recurrence is high. Both prevalence and incidence of kidney stone disease are rising globally, and associated cost are gigantic. Hence, effective, well-tolerated and cheap measures for recurrence prevention are of utmost importance. In this article, we summarize the possibilities for the prevention of idiopathic calcium stones and uric acid stones, which together are responsible for the bulk of kidney stone episodes. Formally, preventive measures can be divided into dietary and pharmacologic interventions. In daily practice, frequently both approaches have to be combined to achieve a successful long-term recurrence prevention. The biggest challenge in the recurrence prevention of kidney stones is to achieve a sustained adherence to preventive measures in the affected patients.Risk factors for urolithiasis Abstract. The prevalence and incidence of kidney stones has continuously increased over the last years. Recent evidence suggests that kidney stones have a substantial morbidity including chronic kidney disease and end stage kidney disease as well as significantly increased risk for cardiovascular diseases. Thus, risk stratification - especially of high-risk patients - is mandatory in the management of kidney stone patients. There is a huge variety in risk factors for nephrolithiasis including general factors (such as young age at manifestation, familial disposition), genetic or acquired diseases with risk of stone formation, drugs etc. Several prediction scores have been developed to assess recurrence risk in kidney stone formers. However, only very few studies have investigated these tools and more evidence is needed in future to proof if these scores reliably predict stone recurrence risk.And which stone type are you? Abstract. Knowledge about the stone type is essential for therapy, prophylaxis and prognosis of kidney stone disease. https://www.selleckchem.com/products/Ispinesib-mesilate(SB-715992).html Stone types can completely change in the course of a stone disease and therefore every kidney stone should be analyzed. This narrative review deals with some aspects of methods for analysis and types of kidney stones, with frequencies of different stone types as well as with general and specific mechanisms of kidney stone formation and seeks to stimulate a more in-depth study of this topic.We evaluated serum albumin as an index for predicting respiratory hospitalization in patients with bronchiectasis. We retrospectively reviewed the medical records of 177 patients with bronchiectasis, categorized them into low and normal albumin groups, and compared their clinical characteristics. The prediction of respiratory hospitalization by factors such as serum albumin level, bronchiectasis severity index (BSI), and FACED score (an acronym derived from five variables of forced expiratory volume in 1 s; FEV1, age, chronic colonization of Pseudomonas aeruginosa, extent of bronchiectasis, and dyspnea) was assessed. There were 15 and 162 patients categorized in the low and normal albumin groups, respectively. The low albumin group had lower body mass index and forced expiratory volume in 1 s, and higher age, frequency of previous respiratory hospitalization, percentage of Pseudomonas colonization, number of affected lobes, BSI and FACED scores, and C-reactive protein (CRP) level, than the normal albumin group. The areas under the receiver operating characteristic curve of serum albumin level and BSI and FACED scores for predicting respiratory hospitalization were 0.732 (95% confidence interval (CI), 0.647-0.816), 0.873 (95% CI, 0.817-0.928), and 0.708 (95% CI, 0.618-0.799), respectively. Albumin level, CRP, modified Medical Research Council score, and chronic Pseudomonas aeruginosa (and other organisms) colonization were independent risk factors for respiratory hospitalization. Low serum albumin level was associated with worse clinical condition, higher severity scores, and respiratory hospitalization in patients with bronchiectasis.BACKGROUND Medication therapy management (MTM) and comprehensive medication management (CMM) have been practiced by clinical pharmacists as a predominantly manual activity with interventions documented in a record-keeping system. Program evaluations, largely based on estimations of projected savings and utilization reductions, have not accurately predicted actual claims and utilization changes, leading many to doubt the efficacy of medication management. OBJECTIVE To assess the impact on actual medical claims of a novel artificial intelligence (AI) platform that identifies members and provides decision support to clinicians in performing telephonic interventions similar to MTM and CMM with high-risk Medicaid members. METHODS This retrospective observational study used mixed-effects regression models that flexibly account for general trends in cost, as measured by actual claims, to identify the amount of savings and associated impact. To study the economics, total cost of care (TCoC), defined as all medicationthan $1B annually by applying the program's observed impact to a similar high-risk cohort (about 1.6%) of Medi-Cal members. Additionally, benefits will accrue to nonmanaged health plans based on the savings themselves. DISCLOSURES There was no external funding for this study. The program itself was funded by Inland Empire Health Plan. The retrospective study was a collaboration of the 3 partners (Surveyor Health, Inland Empire Health Plan, and Preveon Health) each of which funded its additional costs of preparing the study. Kessler, Mebine, E. Von Schweber, and L. Von Schweber are employed by Surveyor Health. McConnell and Jai are employed by Inland Empire Health Plan. Nguyen, Kiroyan, and Ho are employed by Preveon Health. Desai reports fees from Surveyor Health for work on this study. E. Von Schweber and L. Von Schweber have 2 patents licensed to Surveyor Health Unified Evaluation, Presentation and Modification of Healthcare Regimens Method and Apparatus for Information Surveying.Pulmonary hypertension (PH) attributable to left heart disease (LHD) is believed to be the most common form of PH and is strongly associated with increased mortality and morbidity in this patient population. Specific therapies for PH-LHD have not yet been identified and the use of pulmonary artery hypertension-targeted therapies in PH-LHD are not recommended. Endothelin receptor antagonists, phosphodiesterase-5 inhibitors, guanylate cyclase stimulators, and prostacyclins have all been studied in PH-LHD with conflicting results. Understanding the mechanisms underlying PH-LHD could potentially provide novel therapeutic targets. Fibrosis, oxidative stress, and metabolic syndrome have been proposed as pathophysiological components of PH-LHD. Genetic associations have also been identified, offering additional mechanisms with biological plausibility. This review summarizes the evidence and challenges for treatment of PH-LHD and focuses on underlying mechanisms on the horizon that could develop into potential therapeutic targets for this disease.